Biologics Manufacturing Market Size & Growth Forecast 2027–2036, By Segments (Modality, Disease Indication, Mode of Manufacturing), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Modality Segment Analysis: Monoclonal Antibodies (mAbs) (Largest Segment) vs Cell & Gene Therapies (Fastest-Growing Segment)

The monoclonal antibodies (mabs) segment accounted for the largest 2026 market share of 42.79% of the biologics manufacturing market, supported by their extensive use in oncology, autoimmune disorders, inflammatory diseases, and other therapeutic areas. Their established clinical applications, targeted mechanisms of action, and broad adoption across treatment protocols sustain demand for specialized manufacturing capabilities. Producing monoclonal antibodies requires consistent process control, reliable cell culture systems, effective purification technologies, and stringent quality assurance to maintain product safety and efficacy. These requirements support continued investment in manufacturing capacity, process optimization, and scalable production infrastructure. Meanwhile, the cell and gene therapies segment is expected to grow at the fastest rate as advances in personalized medicine and the development of treatments targeting underlying genetic and cellular mechanisms expand the need for specialized manufacturing services. These therapies often involve complex production workflows, specialized biological materials, stringent handling requirements, and individualized or small-batch production processes. Consequently, manufacturers are investing in flexible facilities, advanced process technologies, and quality systems capable of addressing the distinct requirements of cell and gene therapy production, positioning this modality for rapid expansion.

Disease Indication Segment Analysis: Oncology (Largest & Fastest-Growing Segment)

The oncology segment accounted for the largest 41.54% share of the biologics manufacturing market in 2026 and is also expected to register the fastest growth, reflecting the significant role of biologic therapies in cancer treatment and the continued development of targeted and immune-based approaches. Monoclonal antibodies, antibody-based therapies, and other biologics are increasingly important in addressing different cancer types, supporting sustained demand for specialized manufacturing capacity. The complexity of oncology biologics requires stringent control over production processes, product consistency, and quality standards, encouraging manufacturers to strengthen process development, scale-up capabilities, and production reliability. Growth is further supported by continued research into novel cancer therapies and the advancement of treatment approaches that target specific molecular pathways or activate immune responses. As oncology pipelines expand, biologics manufacturers must accommodate diverse product characteristics and evolving production requirements while maintaining regulatory compliance and consistent supply. These dynamics reinforce oncology's position as both the leading disease indication and a key source of incremental demand for biologics manufacturing capabilities.

Mode of Manufacturing Segment Analysis: In-house Manufacturing (Largest Segment) vs Contract Manufacturing (Fastest-Growing Segment)

In-house manufacturing represented the largest segment share of the biologics manufacturing market in 2026, reflecting the preference among established biopharmaceutical companies to retain direct control over production processes, quality management, intellectual property, and supply continuity. Internal manufacturing capabilities allow organizations to align production schedules with development priorities, protect proprietary process knowledge, and maintain close oversight of complex biologics manufacturing operations. This approach is particularly relevant for companies with established production infrastructure, specialized technical expertise, and sustained demand across commercial product portfolios. However, maintaining internal facilities requires substantial capital investment, skilled personnel, ongoing technology upgrades, and rigorous compliance with manufacturing standards. In contrast, contract manufacturing is expected to grow at the fastest rate as biologics developers seek flexible capacity, specialized technical expertise, and alternatives to the cost and time involved in building or expanding their own facilities. Contract manufacturing organizations can support development, clinical production, scale-up, and commercial manufacturing, helping clients manage fluctuating demand and access capabilities for complex biologic modalities. The increasing complexity of production requirements and the need to accelerate development timelines further support outsourcing, although manufacturers must carefully manage technology transfer, quality oversight, and supply-chain coordination.